TAK-020

TAK-020 is a highly selective, orally available covalent inhibitor of Bruton's tyrosine kinase (BTK). It binds irreversibly to the Cys481 residue in BTK's ATP binding site, thereby inhibiting BTK activity. TAK-020 was developed using fragment-based drug discovery and demonstrates high selectivity over other kinases such as Src and Tec. The drug has been investigated primarily for hematologic malignancies and autoimmune diseases, including rheumatoid arthritis and other immune-related conditions. Phase 1 clinical trials have been completed to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics[3][4][5][6].

Other names

compound 3compound3compound-3